TIS 0.00% 0.0¢ tissue therapies limited

australia's next csl?, page-3

  1. 1,075 Posts.
    lightbulb Created with Sketch. 1482
    A great article, Ash81. The profitability data looks reasonable. Margins based on a royalty model should easily exceed 50%, even taking into account manufacturing and other costs (note only micrograms are needed for each dose). Even if the royalty is only at 5%, the earnings potential is clearly huge - and not too far off either. P/E of 0.5 using 5% royalty, or 0.25 using 10%. And improving by 25% each year!!! Why doesn't TIS and its great product get more publicity??
 
watchlist Created with Sketch. Add TIS (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.